DOCSLIB.ORG

Rapid, Sensitive, and Accurate Point-Of-Care Detection of Lethal Amatoxins in Urine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rapid, Sensitive, and Accurate Point-Of-Care Detection of Lethal Amatoxins in Urine toxins Article Rapid, Sensitive, and Accurate Point-of-Care Detection of Lethal Amatoxins in Urine Candace S. Bever 1 , Kenneth D. Swanson 2, Elizabeth I. Hamelin 2 , Michael Filigenzi 3 , Robert H. Poppenga 3, Jennifer Kaae 4, Luisa W. Cheng 1,* and Larry H. Stanker 1 1 Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, Agricultural Research Service, United States Department of Agriculture, 800 Buchanan Street, Albany, CA 94710, USA; [email protected] (C.S.B.); [email protected] (L.H.S.) 2 Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; [email protected] (K.D.S.); [email protected] (E.I.H.) 3 California Animal Health and Food Safety Laboratory System, University of California, 620 West Health Sciences Drive, Davis, CA 95616, USA; msfi[email protected] (M.F.); [email protected] (R.H.P.) 4 Pet Emergency and Specialty Center of Marin, 901 E. Francisco Blvd, San Rafael, CA 94901, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-510-559-6337 Received: 30 January 2020; Accepted: 12 February 2020; Published: 15 February 2020 Abstract: Globally, mushroom poisonings cause about 100 human deaths each year, with thousands of people requiring medical assistance. Dogs are also susceptible to mushroom poisonings and require medical assistance. Cyclopeptides, and more specifically amanitins (or amatoxins, here), are the mushroom poison that causes the majority of these deaths. Current methods (predominantly chromatographic, as well as antibody-based) of detecting amatoxins are time-consuming and require expensive equipment. In this work, we demonstrate the utility of the lateral flow immunoassay (LFIA) for the rapid detection of amatoxins in urine samples. The LFIA detects as little as 10 ng/mL of α-amanitin (α-AMA) or γ-AMA, and 100 ng/mL of β-AMA in urine matrices. To demonstrate application of this LFIA for urine analysis, this study examined fortified human urine samples and urine collected from exposed dogs. Urine is sampled directly without the need for any pretreatment, detection from urine is completed in 10 min, and the results are read by eye, without the need for specialized equipment. Analysis of both fortified human urine samples and urine samples collected from intoxicated dogs using the LFIA correlated well with liquid chromatography–mass spectrometry (LC-MS) methods. Keywords: lateral flow immunoassay; amatoxins; amanitins; point-of-care; mushroom poisoning Key Contribution: The study demonstrates the utility of the lateral flow immunoassay for the rapid detection of amatoxins in urine. 1. Introduction Distinguishing toxic mushrooms from non-toxic ones is highly challenging, even for expert mycologists. Techniques to properly identify a mushroom include detailed morphological examination of the mushroom body, substrate identification, and knowledge of the location and the season. The toxins often associated with lethal cases are cyclopeptides, and more specifically amanitins (most commonly α-amanitin (α-AMA), β-AMA, and γ-AMA, collectively referred to as amatoxins) [1] (Figure1). Amatoxins are found in a few species of mushrooms from di fferent genera, including Amanita, Galerina, and Lepiota [2]. Amatoxins are highly resistant to degradation, and on the cellular Toxins 2020, 12, 123; doi:10.3390/toxins12020123 www.mdpi.com/journal/toxins Toxins 2020, 12, 123 2 of 10 Toxins 2020, 12, x FOR PEER REVIEW 2 of 9 level they inhibit transcription by binding to RNA polymerase II. As little as 0.1 mg/kg body weight of body weight of amatoxins may cause death [3,4], and this amount can be found in a single Amanita amatoxins may cause death [3,4], and this amount can be found in a single Amanita phalloides. phalloides. Compound R1 R2 R3 α-amanitin NH2 OH OH β-amanitin OH OH OH γ-amanitin NH2 OH H (a) (b) Figure 1. Chemical structures of the amatoxin variants examined in this paper, (a) molecular structure Figureof the 1. amanitin, Chemical (b structures) R-group of designations the amatoxin for variants each variant. examined in this paper, (a) molecular structure of the amanitin, (b) R-group designations for each variant. Consumption of toxin-containing mushrooms can result in a range of symptoms, from mild to life-threateningConsumption of [5 toxin-containing,6]. The presumptive mushrooms diagnosis can forresult amatoxin in a range poisoning of symptoms, is based from on amild history to life-threateningof consuming wild[5,6]. mushroomsThe presumptive (if known), diagnosis presentation for amatoxin of delayed poisoning gastroenteritis, is based on elevateda history liver of consumingenzyme levels, wild and mushrooms ruling out other(if known), gastrointestinal presentati diseaseson of ordelayed conditions gastroenteritis, [6]. To distinguish elevated amatoxin liver enzymepoisonings, levels, the and presence ruling of anout amatoxin other gastrointestin in an intoxicatedal diseases patient’s or urineconditions would [6]. provide To distinguish a definitive amatoxindiagnosis. poisonings, For dogs, obtainingthe presence a history of an amatoxin of mushroom in an ingestion intoxicated is rare, patient’s making urine diagnosis would provide even more a definitivechallenging. diagnosis. There areFor only dogs, a fewobtaining laboratories a history capable of mushroom of testing ingestion biological is specimensrare, making for diagnosis amatoxins evento confirm more challenging. human or animal There exposures,are only a few and labora even whentories available,capable of test testing results biological might not specimens be available for amatoxinssoon enough to confirm to help guidehuman treatment. or animal Although exposures, there and are even no when FDA-approved available, antidotes,test results early might diagnosis, not be availableaggressive soon immediate enough to supportive help guide care,treatment. and a Al rangethough of potentialthere are no therapies FDA-approved can potentially antidotes, improve early diagnosis,patient outcomes aggressive [6– 11immediate]. supportive care, and a range of potential therapies can potentially improveFor patient both humans outcomes and [6–11]. dogs, the first symptoms of amatoxin poisonings usually appear 6–24 h afterFor ingestion both humans of an and amatoxin-containing dogs, the first symptoms mushroom of amatoxin [6]. By thispoisonings time, amatoxins usually appear have already6-24 h afterbegun ingestion damaging of an the amatoxin-containing liver and kidneys. Basedmushroom on toxicological [6]. By this time, studies, amatoxins amatoxins have disappear already begun rapidly damagingfrom the serum,the liver but and are kidneys. detectable Based in urineon toxicolo up togical 4 days studies, after amatoxins ingestion [12disappear–14]. In rapidly human from urine, thetoxin serum, concentrations but are detectable decreased in over urine time, up andto 4 thedays highest after ingestion concentrations [12–14]. observed In human were urine, 4820 ngtoxin/mL concentrationsfor α-AMA and decreased 7103 ng/ mLover for time,β-AMA and the [12 highest]. Because concentrations of the relative observed ease of obtainingwere 4820 a ng/mL urine sample, for α- AMAand theand longer 7103 ng/mL duration for ofβ-AMA detectability [12]. Because of amatoxins of the relative in urine ease compared of obtaining to serum, a urine urine sample, seems and an theobvious longer sample duration matrix of detectability for performing of amatoxins rapid amatoxin in urine analysis. compared Sensitive, to serum, rapid, urine and seems easy-to-perform an obvious samplemethods matrix are needed for performing to detect amatoxins rapid amatoxin for the early analysis. diagnosis Sensitive, of toxin rapid, poisoning and [easy-to-perform9,15,16]. methodsCurrent are needed methods to ofdetect chemical amatoxins detection for ofthe amatoxins early diagnosis in urine of include toxin poisoning liquid chromatography–mass [9,15,16]. spectrometryCurrent methods (LC-MS) of methods chemical [ 17detection–23] and of antibody-based amatoxins in urine enzyme-linked include liquid immunosorbent chromatography– assays mass(ELISAs) spectrometry [24,25]. LC-MS (LC-MS) methods methods require [17–23] sample and extractionantibody-based and expensive enzyme-linked equipment, immunosorbent while ELISA assaysmethods (ELISAs) require [24,25]. specialized LC-MS equipment. methods Methodsrequire sa ofmple both extraction types typically and expensive take a few equipment, hours to complete. while ELISALateral methods flow immunoassay require specialized (LFIA) formatsequipment. utilize Methods some of of the both reagents types typically used for ELISA,take a few but hours the entire to complete.test can be Lateral completed flow immunoassay in minutes and (LFIA) requires formats no specialized utilize some equipment. of the reagents used for ELISA, but the entireWe havetest can recently be completed developed in minu an LFIAtes and for requires the detection no specialized of mushroom equipment. amatoxins [26]. As the sensitivityWe have of therecently LFIA developed allows it to an detect LFIA as for little the as de 10tection ng/mL, of we mushroom hypothesized amatoxins that this [26]. test As would the sensitivitybe useful of for the urine LFIA analysis allows init instancesto detect as of little mushroom as 10 ng/mL, poisonings. we hypothesized To test this that hypothesis, this test wewould first beconducted useful for analysis urine analysis of urine in samples instances that of weremushro
Load more

Recommended publications
  • Thesis Is Presented for the Degree of Doctor of Philosophy of Curtin University of Technology
    School of Biomedical Sciences Analysis of Candidate Genes within the 3p14-p22 Region of the Human Genome for Association with Bone Mineral Density Phenotypes Benjamin H Mullin This thesis is presented for the Degree of Doctor of Philosophy of Curtin University of Technology February 2011 To the best of my knowledge and belief this thesis contains no material previously published by any other person except where due acknowledgment has been made. This thesis contains no material which has been accepted for the award of any other degree or diploma in any university. Preface The experimental work contained within this thesis was performed in the Department of Endocrinology & Diabetes at Sir Charles Gairdner Hospital under the supervision of Doctor Cyril Mamotte, Associate Professor Scott Wilson, and Professor Richard Prince. All experimental work in this thesis was performed by myself unless otherwise stated. Benjamin H. Mullin, B.Sc. Publications arising from this thesis Mullin, B. H., Prince, R. L., Dick, I. M., Hart, D. J., Spector, T. D., Dudbridge, F. & Wilson, S. G. 2008. Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis. American Journal of Human Genetics , 82 , 1262-9. Mullin, B. H., Prince, R. L., Mamotte, C., Spector, T. D., Hart, D. J., Dudbridge, F. & Wilson, S. G. 2009. Further genetic evidence suggesting a role for the RhoGTPase-RhoGEF pathway in osteoporosis. Bone , 45 , 387-91. Research grants received during completion of this thesis Wilson, S. G., Prince, R. L., Mamotte C., Mullin B. H. 2008. Influence of the ARHGEF3 gene on bone phenotypes. Arthritis Australia Project Grant ($14,500).
    [Show full text]
  • Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
    Send Orders for Reprints to [email protected] Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 35-65 35 Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins Franco Dosio1,*, Barbara Stella1, Sofia Cerioni1, Daniela Gastaldi2 and Silvia Arpicco1 1Dipartimento di Scienza e Tecnologia del Farmaco, University of Torino, Torino, I-10125, Italy; 2Dipartimento di Bio- tecnologie Molecolari e Scienze per la Salute, University of Torino, Torino, I-10125, Italy Received: December 13, 2012; Accepted: February 21, 2013; Revised: March 7, 2013 Abstract: Antibody-delivered drugs and toxins are poised to become important classes of cancer therapeutics. These bio- pharmaceuticals have potential in this field, as they can selectively direct highly potent cytotoxic agents to cancer cells that present tumor-associated surface markers, thereby minimizing systemic toxicity. The activity of some conjugates is of particular interest receiving increasing attention, thanks to very promising clinical trial results in hematologic cancers. Over twenty antibody-drug conjugates and eight immunotoxins in clinical trials as well as some recently approved drugs, support the maturity of this approach. This review focuses on recent advances in the development of these two classes of biopharmaceuticals: conventional toxins and anticancer drugs, together with their mechanisms of action. The processes of conjugation and purification, as reported in the literature and in several patents, are discussed and the most relevant results in clinical trials are listed. Innovative technologies and preliminary results on novel drugs and toxins, as reported in the literature and in recently-published patents (up to February 2013) are lastly examined. Keywords: Antibody drug conjugate, anticancer agents, auristatins immunotoxin, calicheamicins, cross-linkers, duocarmycins, maytansinoids.
    [Show full text]
  • AMATOXIN MUSHROOM POISONING in NORTH AMERICA 2015-2016 by Michael W
    VOLUME 57: 4 JULY-AUGUST 2017 www.namyco.org AMATOXIN MUSHROOM POISONING IN NORTH AMERICA 2015-2016 By Michael W. Beug: Chair, NAMA Toxicology Committee Assessing the degree of amatoxin mushroom poisoning in North America is very challenging. Understanding the potential for various treatment practices is even more daunting. Although I have been studying mushroom poisoning for 45 years now, my own views on potential best treatment practices are still evolving. While my training in enzyme kinetics helps me understand the literature about amatoxin poisoning treatments, my lack of medical training limits me. Fortunately, critical comments from six different medical doctors have been incorporated in this article. All six, each concerned about different aspects in early drafts, returned me to the peer reviewed scientific literature for additional reading. There remains no known specific antidote for amatoxin poisoning. There have not been any gold standard double-blind placebo controlled studies. There never can be. When dealing with a potentially deadly poisoning (where in many non-western countries the amatoxin fatality rate exceeds 50%) treating of half of all poisoning patients with a placebo would be unethical. Using amatoxins on large animals to test new treatments (theoretically a great alternative) has ethical constraints on the experimental design that would most likely obscure the answers researchers sought. We must thus make our best judgement based on analysis of past cases. Although that number is now large enough that we can make some good assumptions, differences of interpretation will continue. Nonetheless, we may be on the cusp of reaching some agreement. Towards that end, I have contacted several Poison Centers and NAMA will be working with the Centers for Disease Control (CDC).
    [Show full text]
  • Peptide Chemistry up to Its Present State
    Appendix In this Appendix biographical sketches are compiled of many scientists who have made notable contributions to the development of peptide chemistry up to its present state. We have tried to consider names mainly connected with important events during the earlier periods of peptide history, but could not include all authors mentioned in the text of this book. This is particularly true for the more recent decades when the number of peptide chemists and biologists increased to such an extent that their enumeration would have gone beyond the scope of this Appendix. 250 Appendix Plate 8. Emil Abderhalden (1877-1950), Photo Plate 9. S. Akabori Leopoldina, Halle J Plate 10. Ernst Bayer Plate 11. Karel Blaha (1926-1988) Appendix 251 Plate 12. Max Brenner Plate 13. Hans Brockmann (1903-1988) Plate 14. Victor Bruckner (1900- 1980) Plate 15. Pehr V. Edman (1916- 1977) 252 Appendix Plate 16. Lyman C. Craig (1906-1974) Plate 17. Vittorio Erspamer Plate 18. Joseph S. Fruton, Biochemist and Historian Appendix 253 Plate 19. Rolf Geiger (1923-1988) Plate 20. Wolfgang Konig Plate 21. Dorothy Hodgkins Plate. 22. Franz Hofmeister (1850-1922), (Fischer, biograph. Lexikon) 254 Appendix Plate 23. The picture shows the late Professor 1.E. Jorpes (r.j and Professor V. Mutt during their favorite pastime in the archipelago on the Baltic near Stockholm Plate 24. Ephraim Katchalski (Katzir) Plate 25. Abraham Patchornik Appendix 255 Plate 26. P.G. Katsoyannis Plate 27. George W. Kenner (1922-1978) Plate 28. Edger Lederer (1908- 1988) Plate 29. Hennann Leuchs (1879-1945) 256 Appendix Plate 30. Choh Hao Li (1913-1987) Plate 31.
    [Show full text]
  • 615.9Barref.Pdf
    INDEX Abortifacient, abortifacients bees, wasps, and ants ginkgo, 492 aconite, 737 epinephrine, 963 ginseng, 500 barbados nut, 829 blister beetles goldenseal blister beetles, 972 cantharidin, 974 berberine, 506 blue cohosh, 395 buckeye hawthorn, 512 camphor, 407, 408 ~-escin, 884 hypericum extract, 602-603 cantharides, 974 calamus inky cap and coprine toxicity cantharidin, 974 ~-asarone, 405 coprine, 295 colocynth, 443 camphor, 409-411 ethanol, 296 common oleander, 847, 850 cascara, 416-417 isoxazole-containing mushrooms dogbane, 849-850 catechols, 682 and pantherina syndrome, mistletoe, 794 castor bean 298-302 nutmeg, 67 ricin, 719, 721 jequirity bean and abrin, oduvan, 755 colchicine, 694-896, 698 730-731 pennyroyal, 563-565 clostridium perfringens, 115 jellyfish, 1088 pine thistle, 515 comfrey and other pyrrolizidine­ Jimsonweed and other belladonna rue, 579 containing plants alkaloids, 779, 781 slangkop, Burke's, red, Transvaal, pyrrolizidine alkaloids, 453 jin bu huan and 857 cyanogenic foods tetrahydropalmatine, 519 tansy, 614 amygdalin, 48 kaffir lily turpentine, 667 cyanogenic glycosides, 45 lycorine,711 yarrow, 624-625 prunasin, 48 kava, 528 yellow bird-of-paradise, 749 daffodils and other emetic bulbs Laetrile", 763 yellow oleander, 854 galanthamine, 704 lavender, 534 yew, 899 dogbane family and cardenolides licorice Abrin,729-731 common oleander, 849 glycyrrhetinic acid, 540 camphor yellow oleander, 855-856 limonene, 639 cinnamomin, 409 domoic acid, 214 rna huang ricin, 409, 723, 730 ephedra alkaloids, 547 ephedra alkaloids, 548 Absorption, xvii erythrosine, 29 ephedrine, 547, 549 aloe vera, 380 garlic mayapple amatoxin-containing mushrooms S-allyl cysteine, 473 podophyllotoxin, 789 amatoxin poisoning, 273-275, gastrointestinal viruses milk thistle 279 viral gastroenteritis, 205 silibinin, 555 aspartame, 24 ginger, 485 mistletoe, 793 Medical Toxicology ofNatural Substances, by Donald G.
    [Show full text]
  • Toxic Fungi of Western North America
    Toxic Fungi of Western North America by Thomas J. Duffy, MD Published by MykoWeb (www.mykoweb.com) March, 2008 (Web) August, 2008 (PDF) 2 Toxic Fungi of Western North America Copyright © 2008 by Thomas J. Duffy & Michael G. Wood Toxic Fungi of Western North America 3 Contents Introductory Material ........................................................................................... 7 Dedication ............................................................................................................... 7 Preface .................................................................................................................... 7 Acknowledgements ................................................................................................. 7 An Introduction to Mushrooms & Mushroom Poisoning .............................. 9 Introduction and collection of specimens .............................................................. 9 General overview of mushroom poisonings ......................................................... 10 Ecology and general anatomy of fungi ................................................................ 11 Description and habitat of Amanita phalloides and Amanita ocreata .............. 14 History of Amanita ocreata and Amanita phalloides in the West ..................... 18 The classical history of Amanita phalloides and related species ....................... 20 Mushroom poisoning case registry ...................................................................... 21 “Look-Alike” mushrooms .....................................................................................
    [Show full text]
  • New Developments in Amatoxin Poisoning
    New Developments in Amatoxin Poisoning ACMT Annual Scientific Meeting San Juan, PR March 15, 2013 Disclosure S Todd Mitchell MD,MPH Principal Investigator: Prevention and Treatment of Amatoxin Induced Hepatic Failure With Intravenous Silibinin ( Legalon® SIL): An Open Multicenter Clinical Trial Consultant: Madaus-Rottapharm Amatoxin Poisoning: Overview • 95%+ of all fatal mushroom poisonings worldwide are due to amatoxin containing species. • 50-100 Deaths per year in Europe is typical. • Growing Problem in North America, especially Northern Califoriia USA 1976-2005: 126 Reported Cases 2006: 48 Reported Cases, 4 Deaths Summer 2008: 2 Deaths on East Coast September/October 2012: 2 deaths, 1 transplant among 15 total cases on the East Coast. Mexico 2005 & 2006: 19 Reported Deaths. Countless more in SE Asia, Indian Sub-Continent, South Africa Assam, India March 2008: 20 Deaths Swat, Pakistan 2006: Watsonville September 2006 • 57 yo former ER nurse, electrical contractor ingests 8 mushrooms from his property at 1800 on September 8. • Onset of sx ~0200. • Mushrooms identified as Amanita Phalloides by local expert amateur mycologist ~1500. • Presented to ER 24 hours post ingestion: BUN 37, Creat 2.0, Hgb 20.2, Hct 60.5, ALT 96. • Transfer to UCSF 9/10. INR 2.2, ALT 869 after Rx with hydration, antiemetics, repeated doses of charcoal, IV NAC, and IV PEN G. • 72 Hours: INR 4.5, ALT 2274, Bil 4.0. • Liver Transplant 9/14. 2007 Santa Cruz Cohort • EM age 82. ALT 12224, INR 5.4, Factor V 9% @ 72 hours. ALT 3570, INR 1.7, Factor V 49% @ 144 hours. Died from anuric renal failure 1/11.
    [Show full text]
  • |H|||||||||| USOO5278143A United States Patent 19 11 Patent Number: 5,278,143 Shepro Et Al
    |H|||||||||| USOO5278143A United States Patent 19 11 Patent Number: 5,278,143 Shepro et al. (45) Date of Patent: Jan. 11, 1994 (54) PROPHYLACTIC AND THERAPEUTIC OTHER PUBLICATIONS METHODS FOR TREATING NTER LEUKIN-MEDIATED EDEMAS Rudinger, Peptide Hormones, Parsons (Ed.) U. Park t Press, Baltimore, pp. 1-7 (1976). (75) Inventors: David Shepro, Boston, Mass.; J. Doukas et al., Blood, vol. 69, No. 6 pp. 1563-1569 (Jun. Steven Alexander, Nashville, Tenn. 1987). Frimmer, Chem. Abstracts, vol. 71, No. 99937m (1969). 73) Assignee: Trustees of Boston University, Wieland et al., Crit. Rev. Biochem. vol. 5, pp. 185-260 Boston, Mass. (1978). (21) Appl. No.: 807,668 Welbournet al., J. Appl. Physiol 70: 1364-1368 (1991). 22 illed: Dec. 16, 1991 Primary Examiner-Y. Christina Chan 22 Filed ec. 10, Attorney, Agent, or Firm-David Prashker Related U.S. Application Data 57 ABSTRACT m 63 continuation of ser. No. 416,905, Oct. 4, 1989, aban- Unique methods for treating interleukin-mediated ede doned, which is a continuation-in-part of Ser. No. mas in living subjects are provided comprising adminis 47,121, Oct. 4, 1989, abandoned, and a continuation- tering an effective amount of a composition selected in-part of Ser. No. 185,650, Apr. 25, 1988, abandoned. from the group consisting of phallotoxins, phallotoxin analogues, antamanide, or an antananide analogue to 51 Int. Cl. ........................ A61K 37/02; CK /6 the subject. The methods offer prophylactic and thera 52 576.5/35567; 17,353 peutic modes of treatment for both localized and sys s s 8 temic interleukin-mediated edemas. The compositions 58) Field of Search ...................
    [Show full text]
  • The World's Most Poisonous Mushroom, Amanita Phalloides, Is
    Maxwell Moor-Smith, BSc, Raymond Li, BSc(Pharm), MSc, Omar Ahmad, MD, FRCPC The world’s most poisonous mushroom, Amanita phalloides, is growing in BC The expanded range of death cap mushrooms—previously found on the roots of imported European trees but now found in association with native Garry oaks—puts amateur foragers at risk, and recognition of amatoxin poisoning is essential to preventing future fatalities. ABSTRACT: Amatoxins in Amanita acute liver failure occurs. Manage- shown some benefit in a retro- phalloides, commonly known as the ment of the symptomatic patient spective survival analysis. With the death cap mushroom, are responsi- consists of providing supportive expanded range of A. phalloides in ble for 90% of the world’s mushroom- care, promoting renal elimination of BC, physicians should be alert to related fatalities. The most deadly amatoxins, interrupting enterohe- the possibility of amatoxin poison- amatoxin for humans is α-amanitin, patic recirculation of amatoxins, and ing and include it in the differential a bicyclic octapeptide that irrevers- administering proposed antidotes. diagnosis of a patient presenting ibly binds RNA polymerase II, thus Although no established antidote with gastroenteritis or hepatotoxic- preventing protein synthesis and for A. phalloides has been identified, ity and a history of ingesting foraged causing cell death. Three recent N-acetylcysteine and silibinin have mushrooms. poisoning cases in British Columbia show how the death cap can be eas- ily mistaken for edible mushrooms the world’s most poisonous mushroom such as the puffball and the paddy is growing in British Columbia straw mushroom. Since being intro- duced from Europe to the west and mid-Atlantic coasts of North Ameri- Amanita phalloides, commonly known as the death cap mushroom, ca, A.
    [Show full text]
  • 2012 NAMA Toxicology Committee Report North American Mushroom Poisonings by Michael W
    2012 NAMA Toxicology Committee Report North American Mushroom Poisonings By Michael W. Beug, PhD, Chair NAMA Toxicology Committee P.O. Box 116, Husum, WA 98623 [email protected] Abstract In 2012, 35 of the 100 human poisoning cases we have reports for involved amatoxins. The vast majority of the amatoxin cases involved ingestion of the death cap, Amanita phalloides . Other cases involved destroying angels, Amanita ocreata, Amanita bisporigera and similar all-white Amanita species. There were three deaths in the United States from a single incident where elderly residents of a residential care facility were served soup made with deadly Amanita species. There were two deaths in two separate cases in Canada. While we often learn of the majority of amatoxin cases, we only get a small sampling of other mushroom poisonings since they rarely involve death of the victim. Of the cases with symptoms severe enough for the individual to go to the hospital, over 14% were adverse reactions to hallucinogenic mushrooms, predominately Psilocybe species. Chlorophyllum molybdites accounted for 12% of this year’s cases. Adverse reactions to various Morchella species accounted for 10%. We learned of 26 dogs and one horse poisoned by mushrooms, with 11 dog deaths, mostly from amatoxins. In two deaths, Inocybe species were implicated. In one death, two doses of atropine were administered to a dog who had consumed Amanita muscaria . Atropine markedly intensifies the effects of the toxins ibotenic acid and muscimol and so is contraindicated in such cases. In 2012, there were once again many reports of amatoxin poisonings, both in humans (five deaths) and in dogs (six deaths from apparent amatoxins).
    [Show full text]
  • Phalloidin, Amanita Phalloides
    Phalloidin, Amanita phalloides sc-202763 Material Safety Data Sheet Hazard Alert Code EXTREME HIGH MODERATE LOW Key: Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Phalloidin, Amanita phalloides STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH4 HAZARD INSTABILITY0 SUPPLIER Company: Santa Cruz Biotechnology, Inc. Address: 2145 Delaware Ave Santa Cruz, CA 95060 Telephone: 800.457.3801 or 831.457.3800 Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305 Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 PRODUCT USE Toxic bicyclic heptapeptide (a member of the family of phallotoxins) isolated from the green mushroom, Amanitra phalloides Agaricaceae (the green death cap or deadly agaric). Binds to polymeric actin, stabilising it and interfering with the function of endoplasmic reticulum and other actin-rich structures. NOTE: Advice physician prior to working with phallotoxins. Prepare Emergency procedures. SYNONYMS C35-H48-N8-O11-S, phalloidine, "Amanita phalloides Group I toxin", "Amanita phalloides Group I toxin", "mushroom (green death cap/ deadly agaric) phallotoxin/ peptide", "cyclopeptide/ bicyclic bioactive heptapeptide" Section 2 - HAZARDS IDENTIFICATION CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Very toxic by inhalation, in contact with skin and if swallowed. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ■ Severely toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 5 gram may be fatal or may produce serious damage to the health of the individual. ■ At sufficiently high doses the material may be hepatotoxic(i.e.
    [Show full text]
  • Mushrooms Intoxications
    https://doi.org/10.5272/jimab.2018241.1887 Journal of IMAB Journal of IMAB - Annual Proceeding (Scientific Papers). 2018 Jan-Mar;24(1) ISSN: 1312-773X https://www.journal-imab-bg.org Original article MUSHROOMS INTOXICATIONS Petko Marinov1,2, Georgi Bonchev1, Dobri Ivanov3, Snezha Zlateva1,2, Tsonka Dimitrova3, Kaloyan Georgiev4 1) Clinic for Intensive Treatment of Acute Intoxications and Toxicoallergies, Naval Hospital – Varna, Military Medical Academy, Bulgaria 2) Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University – Varna, Bulgaria 3) Department of Biology, Faculty of Pharmacy, Medical University – Varna, Bulgaria 4) Department of Pharmaceutical Technologies, Faculty of Pharmacy, Medical University – Varna, Bulgaria ABSTRACT INTRODUCTION Purpose: To perform a retrospective analysis of Poisonings with mushrooms have an important po- mushroom poisonings in Varna region for 25 years (1991- sition in the ethology of acute exogenous intoxication 2015). Mushroom poisonings account for 10.7% of and are one of the main reasons for hospitalization. They hospitalizations associated with acute exogenous intoxi- occur throughout the world, including the Balkan Penin- cation. Poisoning with Amanita phalloides, Amanita sula. In Turkey, mushroom poisoning comprises the main pantherina, Amanita muscaria and various fungi that part of the plant and fungal toxicities [1]. The most im- cause only gastrointestinal symptoms are of greatest im- portant mushroom poisoning for toxicological practice in portance for the clinical toxicology in the Republic of Southeast Europe is those with Amanita phaloides mush- Bulgaria. rooms. Mushroom poisoning by Amanita phalloides is a Material/Methods: Objects of the study were 1872 rare but potentially fatal disease [2]. Death cap (Amanita patients who received treatment at the Clinic for Inten- phalloides) poisoning is a serious medical condition, caus- sive Treatment of Acute Intoxications and Toxicoallergies, ing organ failure with potentially fatal outcome [3].
    [Show full text]